You are here: Home » Companies » News
Business Standard

Govt asks drug makers to ramp up remdesivir production to full capacity

The government on Wednesday said that all seven manufacturers of remdesivir in the country have been asked to ramp up production to full capacity by next week.

Topics
Pharma Companies | Indian drug makers

Press Trust of India  |  New Delhi 

remdesivir, coronavirus, drugs, covid, pharma

The government on Wednesday said that all seven manufacturers of remdesivir in the country have been asked to ramp up production to full capacity by next week.

The direction comes against reports of shortages of the critical drug.

Remdesivir is considered as a key antiviral drug in the fight against COVID-19, especially in adult patients with severe complications.

"There are seven players who produce remdesivir. I have asked all players to ramp up production to full capacity by next week. The drug's API is manufactured in India so there won't be a problem," Mansukh Mandaviya, Minister of State for Chemical and Fertilizers, told PTI.

Mandaviya said these seven manufacturers - Mylan, Hetero, JubiliantLife Sciences, Cipla, Dr Reddy's, Zydus Cadila and Sun Pharma - have a monthly production capacity of 31.60 lakh vials.

Letters have been despatched to all these drugmakers to ramp up production, he added.

Of the 31.60 lakh vials, Hetero produces 10.50 lakh vials a month, Cipla makes 6.20 lakh vials, 5 lakh vials are produced by Zydus Cadila and 4 lakh vials are produced by Mylan, Mandaviya said.

The remaining drugmakers produce vials in the range of 1 lakh and 2.5 lakh a month, he added.

The Madhya Pradesh government has decided to procure Remdesivir injections so that they could be provided free of cost for the treatment of critical COVID-19 patients from the economically weaker sections.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, April 07 2021. 21:29 IST
RECOMMENDED FOR YOU
.